PHILADELPHIA, PA, May 11, 2026 – Exegenesis Bio, biopharmaceutical company focused on gene therapies and oligonucleotide-based drugs with globally leading delivery vector technologies, is pleased to announce that two oral presentations and three posters will be presented at American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting, May 11-15, 2026 in Boston, MA.
Oral Presentations
Title: Transferrin receptor-targeting AAV achieved superior and broad CNS transduction in multiple
species after intravenous administration
Session: AAV capsid engineering IV
Time: 8:45 – 9:00 AM (ET), May 15, 2026
Abstract #: 425
Presenter: Zhenhua Wu, Ph.D.
Title: AAV-Mediated RNA Interference Targeting Nav1.7 Provides Durable Relief of Hyperalgesia in Preclinical Models of Chronic Pain
Session: Neurologic diseases VII
Time: 11:00 – 11:15 pm (ET), May 15, 2026
Abstract #: 487
Presenter: Chunjuan Song, Ph.D.
Poster Presentations
Title: Neutralizing antibody resistant AAV9 capsid variants generated by directed evolution
Time: 5:00– 6:30 pm (ET), May 13, 2026
Abstract #: 2024
Title: Engineered AAV capsids with enhanced muscle tropism and reduced hepatic transduction
Time: 5:00– 6:30 pm (ET), May 14, 2026
Abstract #: 3024
Title: EXG202: An AI-Engineered AAV Gene Therapy Enabling Multi-Pathway Angiogenic Suppression in Fundus Neovascular Diseases
Time: 5:00– 6:30 pm (ET), May 14, 2026
Abstract #: 3365
For further information please contact: BD@ExegenesisBio.com